MRSA and VRE

On this page

MRSA - The Staph Superbug

  • Mechanism: The mecA gene encodes Penicillin-Binding Protein 2a (PBP2a). This altered protein has a low affinity for β-lactam antibiotics, conferring resistance by preventing their binding.

  • Clinical Syndromes:

    • Community-Associated (CA-MRSA): Presents as skin/soft tissue infections (abscesses, boils). Virulence is often driven by Panton-Valentine Leukocidin (PVL) toxin.
    • Hospital-Associated (HA-MRSA): Causes more invasive disease (bacteremia, pneumonia, endocarditis) in patients with recent healthcare exposure.
  • Diagnosis:

    • Rapid: NAAT for the mecA gene offers fast identification.
    • Culture: Chromogenic agar for screening; Kirby-Bauer testing with a cefoxitin disk confirms resistance.

⭐ The PVL toxin in CA-MRSA is linked to severe, necrotizing pneumonia, classically seen in healthy patients following an influenza infection.

VRE - Vexing Vancomycin Villain

Vancomycin Resistance: VanA-type D-Ala-D-Lac Synthesis

  • Mechanism: Acquired vanA or vanB genes alter the peptidoglycan precursor target.
    • Terminal $D-Ala-D-Ala$ is changed to $D-Ala-D-Lac$.
    • This substitution prevents vancomycin from binding effectively.
  • Predominant Species:
    • Enterococcus faecium is more frequently vancomycin-resistant than E. faecalis.
  • Key Risk Factors:
    • Prolonged hospitalization or ICU stay.
    • Long-term antibiotic therapy, especially with vancomycin.
  • Clinical Syndromes:
    • Nosocomial infections, including UTIs, bacteremia, and endocarditis.

⭐ VRE can transfer its resistance genes to other bacteria, such as S. aureus, leading to the emergence of Vancomycin-Resistant Staphylococcus aureus (VRSA).

Treatment - The Resistance Rumble

DrugMechanism & Key Side EffectMRSAVRE
VancomycinInhibits cell wall synthesis by binding D-Ala-D-Ala. → Red Man Syndrome, nephrotoxicity.
DaptomycinLipopeptide; depolarizes cell membrane. → Myopathy (monitor CPK).
LinezolidBinds 50S subunit. → Thrombocytopenia, Serotonin Syndrome (risk with SSRIs).
Ceftaroline5th-gen cephalosporin; binds PBP2a. → Hemolytic anemia.
TigecyclineBinds 30S subunit. → Severe nausea/vomiting; ↑ mortality warning.
  • MRSA resistance stems from the mecA gene, encoding an altered penicillin-binding protein (PBP2a), making it impervious to most beta-lactams.
  • VRE resistance arises from the conversion of the peptidoglycan precursor from D-Ala-D-Ala to D-Ala-D-Lac.
  • Key MRSA treatments include Vancomycin, Linezolid, and Daptomycin.
  • For VRE, preferred agents are Linezolid and Daptomycin.
  • Both are significant causes of nosocomial infections, particularly in immunocompromised patients.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: MRSA and VRE

Test your understanding with these related questions

A 33-year-old man presents to the emergency department complaining of weakness and fatigue. He states that his symptoms have worsened over the past day. He has a past medical history of IV drug abuse and alcoholism and he currently smells of alcohol. His temperature is 102°F (38.9°C), blood pressure is 111/68 mmHg, pulse is 110/min, respirations are 17/min, and oxygen saturation is 98% on room air. Physical exam is notable for focal tenderness over the lumbar spine. Initial lab values and blood cultures are drawn and are notable for leukocytosis and an elevated C-reactive protein (CRP). Which of the following is the best treatment for this patient?

1 of 5

Flashcards: MRSA and VRE

1/10

_____ is a -lactamase producing bacteria resistant to penicillin.

TAP TO REVEAL ANSWER

_____ is a -lactamase producing bacteria resistant to penicillin.

Staph aureus

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free